Journal of Developing Drugs

Journal of Developing Drugs
Open Access

ISSN: 2329-6631

+44 1478 350008

Hossein Omidian

Hossein Omidian
Pharmaceutical Sciences,
3200 S University Drive, Fort Lauderdale,FL 33328

  • Review Article
    Opioid Abuse and Deterrence: Buprenorphine Products
    Author(s): Rashel Nimroozi, Hossein Omidian and David J MastropietroRashel Nimroozi, Hossein Omidian and David J Mastropietro

    Abuse of opioid based prescription drugs is an ongoing global health concern that affects millions of individuals worldwide. The economic burden from this abuse has led to the development of treatment programs and the use of methadone maintenance in clinics. Yet, methadone itself has abuse liability and is misused in ways such as crushed for nasal insufflation or dissolved for subsequent intravenous injection. Later, a newer synthetic opioid working as a partial agonist at the mu-opioid receptor, buprenorphine (Subutex®), became available for outpatient use.This new opioid produces restricted euphoria, decreases withdrawal symptoms, and can prevent displacement of buprenorphine should the user decide to take illicit opioids. Due to high risk of abuse, the product was discontinued and now only available as a combination (Suboxone®) with the opioid antagonist naloxone.Users who .. View More»
    DOI: 10.4172/2329-6631.1000117

    Abstract PDF

Relevant Topics